Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21621304 | 0.81 | L3MBTL1 (0.58) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL5850146 | 0.78 | MAPK14 (0.49) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL7670525 | 0.78 | MAPK14 (0.62) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL5850429 | 0.77 | PTGS2 (0.57) | MAPK14CSNK1DGCGRCSNK1EALDH1A1 | |
| SCHEMBL1554639 | 0.76 | MAPK14 (0.54) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL6579207 | 0.76 | MAPK14 (0.53) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL1878087 | 0.74 | MAPK14 (0.48) | MAPK14CSNK1DJAK3GCGRCCNA2 | |
| SCHEMBL6488266 | 0.74 | MAPK14 (0.54) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL6619193 | 0.73 | MAPK14 (0.53) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL7982783 | 0.73 | MAPK14 (0.50) | MAPK14CSNK1DJAK3CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1294129-C | Heteraryl-substituted porrole derivatives, their prep. and therapeutic use | SANKYO CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1525968-A | composition for preventing or treating liver disease | 三共株式会社 | 2004-09-01 | — | — | CN | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| CN-1295069-A | Heteraryl-substituted porrole derivatives, their prep. and therapeutic use | SANKYO CO (JP) | 2001-05-16 | — | — | CN | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MAPK14 3902/4885CSNK1D 504/4885JAK3 1896/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | MAPK14 4157/4885CSNK1D 669/4885JAK3 1352/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | MAPK14 3593/4885CSNK1D 1251/4885JAK3 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.